Checkpoint Therapeutics (CKPT) 10-Q2024 Q1 Quarterly report

Exhibit 32.1

​

CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER

PURSUANT TO 18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

​

I, James F. Oliviero, Chief Executive Officer of Checkpoint Therapeutics, Inc. (the “Company”), in compliance with 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certify that, to the best of my knowledge, the Company’s Quarterly Report on Form 10-Q for the period ended March 31, 2024 (the “Report”) filed with the Securities and Exchange Commission:

​

· Fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

​

· The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

​

​